ES2671639T3 - Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca - Google Patents

Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca Download PDF

Info

Publication number
ES2671639T3
ES2671639T3 ES13848937.2T ES13848937T ES2671639T3 ES 2671639 T3 ES2671639 T3 ES 2671639T3 ES 13848937 T ES13848937 T ES 13848937T ES 2671639 T3 ES2671639 T3 ES 2671639T3
Authority
ES
Spain
Prior art keywords
clevidipine
blood pressure
patient
pharmaceutical composition
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13848937.2T
Other languages
English (en)
Spanish (es)
Inventor
Edward C. SPINDLER Jr.
Loretta M. ITRI
Gregory Charles Williams
Ming-yi HU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2671639T3 publication Critical patent/ES2671639T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13848937.2T 2012-10-26 2013-10-26 Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca Active ES2671639T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US201261719127P 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (1)

Publication Number Publication Date
ES2671639T3 true ES2671639T3 (es) 2018-06-07

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13848937.2T Active ES2671639T3 (es) 2012-10-26 2013-10-26 Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca

Country Status (18)

Country Link
US (1) US10881645B2 (enExample)
EP (1) EP2925128B1 (enExample)
JP (2) JP6329957B2 (enExample)
KR (1) KR102299073B1 (enExample)
CN (2) CN110840890A (enExample)
AU (1) AU2013334081B2 (enExample)
BR (1) BR112015009291B1 (enExample)
CA (1) CA2889584C (enExample)
EA (1) EA030354B1 (enExample)
ES (1) ES2671639T3 (enExample)
IL (1) IL238462A0 (enExample)
MX (1) MX359768B (enExample)
NZ (1) NZ708511A (enExample)
PL (1) PL2925128T3 (enExample)
TR (1) TR201807636T4 (enExample)
UA (1) UA117571C2 (enExample)
WO (1) WO2014066870A1 (enExample)
ZA (1) ZA201503741B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385243B (es) * 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
CN102186351A (zh) 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
EP2498731B1 (en) * 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
CN110840890A (zh) 2020-02-28
NZ708511A (en) 2018-11-30
BR112015009291B1 (pt) 2021-03-16
CA2889584C (en) 2018-08-14
MX359768B (es) 2018-10-10
EA030354B1 (ru) 2018-07-31
KR20150104084A (ko) 2015-09-14
PL2925128T3 (pl) 2018-10-31
EP2925128A1 (en) 2015-10-07
JP2018065875A (ja) 2018-04-26
EA201590825A1 (ru) 2015-09-30
EP2925128A4 (en) 2016-06-08
IL238462A0 (en) 2015-06-30
CN104968199A (zh) 2015-10-07
ZA201503741B (en) 2022-09-28
AU2013334081A1 (en) 2015-06-11
BR112015009291A2 (pt) 2017-07-04
AU2013334081B2 (en) 2017-05-18
US10881645B2 (en) 2021-01-05
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
KR102299073B1 (ko) 2021-09-09
TR201807636T4 (tr) 2018-06-21
US20140121247A1 (en) 2014-05-01
JP6329957B2 (ja) 2018-05-23
EP2925128B1 (en) 2018-04-11
WO2014066870A1 (en) 2014-05-01
UA117571C2 (uk) 2018-08-27
MX2015005341A (es) 2016-05-24

Similar Documents

Publication Publication Date Title
ES2584509T3 (es) Composiciones para el tratamiento del ictus o accidente cerebrovascular con un agonista del receptor de endotelina B
US10493124B2 (en) Angiotensin II alone or in combination for the treatment of hypotension
ES2914060T3 (es) Combinación de dofetilida y mexiletina para la prevención y el tratamiento de la fibrilación auricular
US10987332B2 (en) Sprayable aqueous composition comprising glyceryl trinitrate
ES2569123T3 (es) Infusión lenta de sulcardina y sus sales
US20220313671A1 (en) Short-Acting Dihydropyridines (Clevidipine) For Use in Reducing Stroke Damage
CA2889584C (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
EP2854794B1 (en) Stabilized granules containing glyceryl trinitrate for inducing arteriogenesis
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
ES2380913T3 (es) Uso de L-carnitina para el tratamiento de enfermerdades cardiovasculares
HK1093869A1 (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
HK1093869B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes